Romiplostim with standard therapy for severe aplastic anemia
Part of Blood & lymphatic clinical trials.
This trial tests combining a drug called romiplostim (a bone marrow stimulant) with standard immunosuppressive therapy as a first treatment for severe aplastic anemia. It aims to improve blood cell counts and reduce the need for transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older
- You have a diagnosis of severe or very severe aplastic anemia
- You are not able or willing to have a stem cell transplant
- You can carry out daily activities with little or no help
- You have not received more than 4 weeks of certain prior treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called romiplostim to see if it can help people with non-severe aplastic anemia (NSAA) who still need regular blood transfusions even after standard treatments. Romiplostim works by stimulating your body to make more blood cells, which may reduce your need for transfusions.
This trial tests a new drug called ropustine to see if it can help people with aplastic anemia that hasn't responded to other treatments. The study is at one hospital and will monitor how well your blood counts and symptoms improve.
This trial tests a drug called romiplostim (Nplate) for patients whose aplastic anemia—a rare blood disorder where the bone marrow stops making enough blood cells—didn't improve after cancer treatment and hasn't responded to other medications. The drug may help your bone marrow produce more blood cells.
This trial tests adding romiplostim to standard care for severe aplastic anemia (a condition where the bone marrow doesn't make enough blood cells) in patients aged 2 to 21. It aims to see if this combination improves blood cell counts in those newly diagnosed or whose disease has come back or not responded to prior treatment.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.